Stocktoria
Replimune Group, Inc. REPL
Replimune Group, Inc. financials (annual)
Bars are annual figures from 2018 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $221.2M | $189.4M | $175.0M | $126.5M | $79.5M | $56.8M | $38.8M | $22.2M | $13.5M |
| SG&A expense | $98.7M | $72.2M | — | — | — | — | — | — | — |
| Operating income | -$319.9M | -$261.6M | -$234.8M | -$177.1M | -$118.3M | -$80.0M | -$56.2M | -$30.9M | -$19.2M |
| Income tax | -$551,000 | $468,000 | $408,000 | $288,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$313.9M | -$247.3M | -$215.8M | -$174.3M | -$118.0M | -$80.9M | -$52.6M | -$30.8M | -$19.7M |
| EPS (diluted) | $-3.38 | $-3.07 | $-3.24 | $-2.99 | $-2.26 | $-1.75 | — | — | — |
| Operating cash flow | -$280.3M | -$192.2M | -$185.5M | -$128.1M | -$82.2M | -$61.4M | -$60.6M | -$25.4M | -$16.0M |
| Free cash flow | — | — | — | -$130.3M | -$84.5M | -$63.8M | -$67.1M | -$28.0M | -$16.1M |
| Cash & equivalents | $209.0M | $111.1M | $74.5M | $146.6M | $105.9M | $182.5M | $59.5M | $25.7M | $17.6M |
| Total assets | $332.4M | $551.3M | $487.7M | $646.6M | $461.2M | $543.1M | $234.1M | $154.3M | $65.2M |
| Total liabilities | $166.2M | $135.5M | $113.2M | $91.3M | $50.0M | $44.4M | $50.4M | $16.5M | $6.9M |
| Shareholders' equity | $166.2M | $415.8M | $374.5M | $555.3M | $411.2M | $498.7M | $183.7M | $137.9M | -$28.1M |
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.